The role of essential fatty acids in chronic fatigue syndrome - A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA

Citation
G. Warren et al., The role of essential fatty acids in chronic fatigue syndrome - A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA, ACT NEUR SC, 99(2), 1999, pp. 112-116
Citations number
11
Categorie Soggetti
Neurology,"Neurosciences & Behavoir
Journal title
ACTA NEUROLOGICA SCANDINAVICA
ISSN journal
00016314 → ACNP
Volume
99
Issue
2
Year of publication
1999
Pages
112 - 116
Database
ISI
SICI code
0001-6314(199902)99:2<112:TROEFA>2.0.ZU;2-W
Abstract
Objective - To replicate the treatment study by Behan et al. (1990) using c urrent research criteria for Chronic Fatigue Syndrome (CFS). Method - Fifty patients who fulfilled the Oxford Criteria for CFS were randomly allocated to treatment with either Efamol Marine or placebo for 3 months. They were seen monthly and completed a physical symptoms checklist and the Beck Inven tory for Depression and reported if they were the same, better or worse at the end of the study. Results - Symptoms generally improved with time but. not significantly and there were no significant differences between the tre atment and placebo groups. Pretreatment red-cell membrane (RBC) lipids of p atients compared with age- and sex-matched normal controls showed no signif icant differences. Discussion - The results of this study contrast sharply with the previous study where 85% of patients had a clinically significant improvement of symptoms with Efamol Marine over a 3-month treatment period.